Current knowledge on cannabinoids in oral fluid

被引:79
作者
Lee, Dayong [1 ]
Huestis, Marilyn A. [1 ]
机构
[1] Natl Inst Drug Abuse, Natl Inst Hlth, Chem & Drug Metab Intramural Res Program, Baltimore, MD 21224 USA
关键词
oral fluid; cannabis; delta-9-tetrahydrocannabinol; marijuana; saliva; cannabinoid; ILLICIT DRUG-USE; PERFORMANCE LIQUID-CHROMATOGRAPHY; EXTERNAL QUALITY ASSESSMENT; POSITIVE PREVALENCE RATES; SOLID-PHASE EXTRACTION; CHRONIC PAIN; GAS-CHROMATOGRAPHY; 11-NOR-DELTA(9)-TETRAHYDROCANNABINOL-9-CARBOXYLIC ACID; DELTA(9)-TETRAHYDROCANNABINOL THC; MARIJUANA USE;
D O I
10.1002/dta.1514
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Oral fluid (OF) is a new biological matrix for clinical and forensic drug testing, offering non-invasive and directly observable sample collection reducing adulteration potential, ease of multiple sample collections, lower biohazard risk during collection, recent exposure identification, and stronger correlation with blood than urine concentrations. Because cannabinoids are usually the most prevalent analytes in illicit drug testing, application of OF drug testing requires sufficient scientific data to support sensitive and specific OF cannabinoid detection. This review presents current knowledge of OF cannabinoids, evaluating pharmacokinetic properties, detection windows, and correlation with other biological matrices and impairment from field applications and controlled drug administration studies. In addition, onsite screening technologies, confirmatory analytical methods, drug stability, and effects of sample collection procedure, adulterants, and passive environmental exposure are reviewed. Delta-9-tetrahydrocannabinol OF concentrations could be >1000 mu g/L shortly after smoking, whereas minor cannabinoids are detected at 10-fold and metabolites at 1000-fold lower concentrations. OF research over the past decade demonstrated that appropriate interpretation of test results requires a comprehensive understanding of distinct elimination profiles and detection windows for different cannabinoids, which are influenced by administration route, dose, and drug use history. Thus, each drug testing program should establish cut-off criteria, collection/analysis procedures, and storage conditions tailored to its purposes. Building a scientific basis for OF testing is ongoing, with continuing OF cannabinoids research on passive environmental exposure, drug use history, donor physiological conditions, and oral cavity metabolism needed to better understand mechanisms of cannabinoid OF disposition and expand OF drug testing applicability. Published 2013. This article is a U.S. Government work and is in the public domain in the USA.
引用
收藏
页码:88 / 111
页数:24
相关论文
共 247 条
[1]   Concordance between verbal report and urine screen of recent marijuana use in adolescents [J].
Akinci, IH ;
Tarter, RE ;
Kirisci, L .
ADDICTIVE BEHAVIORS, 2001, 26 (04) :613-619
[2]  
[Anonymous], 2010, WORLD DRUG REP 2010
[3]  
[Anonymous], DASIS SER S
[4]  
[Anonymous], 2012, REP NO SAL NO E 12 1
[5]  
[Anonymous], 2013, DRUGS FDA FDA APPR D
[6]   Review: The physiology of saliva and transfer of drugs into saliva [J].
Aps, JKM ;
Martens, LC .
FORENSIC SCIENCE INTERNATIONAL, 2005, 150 (2-3) :119-131
[7]   Acute cannabis consumption and motor vehicle collision risk: systematic review of observational studies and meta-analysis [J].
Asbridge, Mark ;
Hayden, Jill A. ;
Cartwright, Jennifer L. .
BMJ-BRITISH MEDICAL JOURNAL, 2012, 344
[8]   Adverse effects of cannabis and cannabinoids [J].
Ashton, CH .
BRITISH JOURNAL OF ANAESTHESIA, 1999, 83 (04) :637-649
[9]   Pharmacology and effects of cannabis: a brief review [J].
Ashton, CH .
BRITISH JOURNAL OF PSYCHIATRY, 2001, 178 :101-106
[10]   Simultaneous Screening and Quantification of 29 Drugs of Abuse in Oral Fluid by Solid-Phase Extraction and Ultraperformance LC-MS/MS [J].
Badawi, Nora ;
Simonsen, Kirsten Wiese ;
Steentoft, Anni ;
Bernhoft, Inger Marie ;
Linnet, Kristian .
CLINICAL CHEMISTRY, 2009, 55 (11) :2004-2018